A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)

Abroad (travel likely)RecruitingPHASE2

Conditions

Ocular Graft Versus Host Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sydney Eye Hospital, Sydney, New South Wales, Australia
Contact: Study coordinator (Stephanie Watson) · stephanie.watson@sydney.edu.au · +61 02 9385 6551
OTA, Brisbane, Queensland, Australia
Contact: Study coordinator (Mark Hinds) · 61 7 3608 2074
Royal Melbourne Hospital, Melbourne, Victoria, Australia
Contact: Study coordinator (Elaine Ass. Professor) · elaine@irissurgey.com.au · +61 413 668 695

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

Persistent Corneal Epithelial Defect

Abroad (travel likely)RecruitingPHASE3

Huntington Beach, United States · Laguna Hills, United States

An Efficacy and Safety Study of DFL24498 in the Treatment of AKC

Atopic Keratoconjunctivitis

Abroad (travel likely)RecruitingPHASE3

Jacksonville, United States · Miami, United States